vs-6766
Showing 1 - 6 of 6
Breast Cancer, Hormone Receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer Trial in Boston
Not yet recruiting
- Breast Cancer
- +2 more
- VS-6766
- +2 more
-
Boston, Massachusetts
- +2 more
Nov 3, 2022
Food Effect Trial in Tempe (VS-6766)
Completed
- Food Effect
- VS-6766
-
Tempe, ArizonaCelerion
May 6, 2022
Mesonephric Gynecologic Cancer Trial in United States (VS-6766, Defactinib)
Recruiting
- Mesonephric Gynecologic Cancer
- VS-6766
- Defactinib
-
Basking Ridge, New Jersey
- +6 more
Mar 15, 2023
Solid Tumours, Multiple Myeloma, Lung Cancer Trial in Sutton, London (VS-6766, Everolimus)
Recruiting
- Solid Tumours
- +2 more
- VS-6766
- Everolimus
-
Sutton, Surrey, United Kingdom
- +1 more
Apr 25, 2022
Colorectal Cancer, Colorectal Adenocarcinoma, Colorectal Cancer Metastatic Trial in Chicago (VS-6766, Cetuximab, Pill Diary)
Not yet recruiting
- Colorectal Cancer
- +4 more
- VS-6766
- +2 more
-
Chicago, IllinoisUniversity of Chicago Medical Center
Jan 6, 2022
NSCLC, Low Grade Serous Ovarian Cancer, Endometrioid Carcinoma Trial in United Kingdom (VS-6766, Defactinib)
Recruiting
- NSCLC
- +3 more
- VS-6766
- Defactinib
-
Manchester, Greater Manchester, United Kingdom
- +4 more
Mar 18, 2022